Skip to main content
Fig. 1 | Trials

Fig. 1

From: The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis

Fig. 1

Designs of the 1366.0021 and 1366.0029 phase II trials

AE adverse event, ALD alcohol-related liver disease, BID twice daily, CAP controlled attenuation parameter, CTCAE Common Terminology Criteria for Adverse Events, D Day, HBV hepatitis B virus, HCV hepatitis C virus, HVPG hepatic venous pressure gradient, LS liver stiffness, LSM liver stiffness measurement, NASH non-alcoholic steatohepatitis, PK pharmacokinetic, QD once daily, SS spleen stiffness, SSM spleen stiffness measurement, TE transient elastography, W week.

Back to article page

Trials

ISSN: 1745-6215